Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab pharmacokinetics in second-line advanced gastric or gastroesophageal junction adenocarcinoma
2014-003791-23Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and gastric cancer (GC), sponsored by Eli Lilly and Company. Primary endpoint: Minimum ramucirumab concentration in serum. Started Mar 2015; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on 2014-003791-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003791-23.